Compare LTC Properties Inc (LTC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Revvity Inc — how do they compare? LTC Properties Inc trades at $42.46 (market cap $2.27B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 7.5× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.42%). Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and Revvity Inc for 12 Days on average.
| LTC | RVTY | |
|---|---|---|
Market Cap | $2.27B | $16.98B |
Volume | 574,171 | 1,456,900 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $157.36 |
52-Week Low | $33.98 | $82.26 |
Typical Hold Time | 88 Days | 12 Days |
Enterprise Value | $3.01B | $19.30B |
Dividend Yield | 5.42% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.05, up 0.57% today, with a mixed technical picture showing bearish overall signals but bullish moving averages. The REIT demonstrates strong fundamentals with 38.93% net income margin and consistent dividend payments. Recent acquisitions totaling $160 million in senior housing properties signal aggressive growth strategy, while analyst consensus targets $49.67 with 32% buy ratings.
LTC presents a balanced opportunity with steady income from monthly dividends and strategic SHOP portfolio expansion, though elevated debt levels and rising interest rates pose headwinds. The stock trades below analyst targets but faces execution risks in its transition to 75% SHOP NOI by 2028.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
